I-Mab Enters into Strategic Regional Partnership with Kalbe Genexine Biologics for Commercialization Rights of CD73 Antibody, TJD5, for Immuno-Oncology

NEXT STORY
PhaseBio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Recent Business Highlights
PREV STORY
Rhythm Pharmaceuticals Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Setmelanotide in POMC and LEPR Deficiency Obesities
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Plant-Derived and Botanical Drugs to Reach Nearly $40B by 2022

WELLESLEY, Mass., Dec. 05, 2017 (GLOBE NEWSWIRE) -- There has been rising interest in ...

author_avatar
NASDAQ Market News

Argos Therapeutics Announces Interim Analysis of Phase 3 ADAPT Trial to be Presented at ESMO 2017 Congress

DURHAM, N.C., Aug. 21, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology ...

author_avatar
NASDAQ Market News

Cyclacel Pharmaceuticals to Release First Quarter 2017 Financial Results

BERKELEY HEIGHTS, N.J., May 05, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ...

author_avatar
NASDAQ Market News